What share options does Joseph Sollee hold in MDxHealth SA (MDXH)?

Joseph Sollee holds multiple share options over MDxHealth ordinary shares. Individual grants include underlying share amounts such as 23,000, 20,000, 65,000, 100,000, and 200,000 ordinary shares, each tied to specific grant dates, exercise prices, vesting schedules, and expiration dates.

When do Joseph Sollee’s MDXH share options expire?

The reported share options have expiration dates ranging from July 24, 2029 through April 11, 2035. Each grant lists a specific expiration date, reflecting the long-term nature of Sollee’s incentive awards tied to MDxHealth ordinary shares.

MDxHealth officer reports option holdings

Q: What does the MDXH Form 3 filing by Joseph Sollee report?

The Form 3 for MDxHealth SA (MDXH) reports officer Joseph Sollee’s existing share option holdings. It lists several option grants over ordinary shares, detailing exercise prices, vesting conditions, and expiration dates, but does not show any recent purchases or sales.

Q: What are some exercise prices for Joseph Sollee’s MDXH options?

The filing shows exercise prices including 12.40 Euros, 8.00 Euros, 13.75 Euros, and 6.84 Euros for earlier grants, plus $2.62 and $1.47 per share for more recent awards, each associated with its respective grant and shareholder meeting approval dates.

Q: How do Joseph Sollee’s MDXH options vest according to the Form 3?

Some options vest in three equal installments on each of the first three anniversaries of the grant date. Other grants vest upon achieving specified company performance criteria evaluated by MDxHealth’s Board of Directors at the end of defined performance periods.

MDxHealth SA officer Joseph Sollee filed an initial Form 3 describing his holdings of share options over ordinary shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

MDxHealth SA officer Joseph Sollee filed an initial Form 3 describing his holdings of share options over ordinary shares. The filing lists multiple option grants with varying exercise prices in euros and U.S. dollars, different vesting schedules including performance-based vesting, and expirations extending through 2035.

Insider Trade Summary

11 transactions reported

Mixed 11 txns

Insider Sollee Joseph

Role See Remarks

Type	Security	Shares	Price	Value
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--
holding	Share Option	--	--	--

Holdings After Transaction: Share Option — 510,350 contracts (Direct)

Footnotes (11)

F1. Represents options to purchase ordinary shares at a price per share of 12.40 Euros granted on May 14, 2019 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 24, 2019. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
F2. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
F3. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
F4. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
F5. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
F6. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
F7. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
F8. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
F9. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
F10. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the performance periods.
F11. Represents options to purchase ordinary shares at a price per share of $1.47 granted on March 26, 2025 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on April 11, 2025. The options vest in three equal installments on each of the first three anniversaries of the date of grant.

Key Figures

Option grant size: 23,000 underlying shares Exercise price: 12.40 Euros/share Exercise price: 8.00 Euros/share +4 more

7 metrics

Option grant size 23,000 underlying shares Share option over ordinary shares expiring July 24, 2029

Exercise price 12.40 Euros/share Options granted May 14, 2019; shareholder resolution July 24, 2019

Exercise price 8.00 Euros/share Options granted June 24, 2020; resolution July 15, 2020

Exercise price 13.75 Euros/share Options granted June 23, 2021; resolution July 3, 2021

Exercise price 6.84 Euros/share Options granted May 12, 2022; resolution August 3, 2022

Recent grant size 100,000 underlying shares Options at $2.62/share expiring June 22, 2034

Recent grant size 200,000 underlying shares Options at $1.47/share expiring April 11, 2035

Key Terms

share option, extraordinary general shareholders' meeting, vesting, performance criteria, +1 more

5 terms

extraordinary general shareholders' meeting regulatory

"issued pursuant to a resolution of an extraordinary general shareholders' meeting"

A meeting of a company's shareholders called outside the regular annual meeting to decide urgent or special matters that cannot wait for the annual gathering. Like an emergency town hall, it is used to vote on significant issues such as large mergers, changes to the board, amendments to corporate bylaws, or major financing decisions, and it matters to investors because the outcomes can quickly change a company’s strategy, ownership structure, or financial prospects.

vesting financial

"The options vest in three equal installments on each of the first three anniversaries"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

performance criteria financial

"vested upon the achievement of certain Company performance criteria evaluated by the Board"

underlying ordinary shares financial

"Represents options to purchase ordinary shares at a price per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the MDXH Form 3 filing by Joseph Sollee report?

The Form 3 for MDxHealth SA (MDXH) reports officer Joseph Sollee’s existing share option holdings. It lists several option grants over ordinary shares, detailing exercise prices, vesting conditions, and expiration dates, but does not show any recent purchases or sales.

What are some exercise prices for Joseph Sollee’s MDXH options?

The filing shows exercise prices including 12.40 Euros, 8.00 Euros, 13.75 Euros, and 6.84 Euros for earlier grants, plus $2.62 and $1.47 per share for more recent awards, each associated with its respective grant and shareholder meeting approval dates.

How do Joseph Sollee’s MDXH options vest according to the Form 3?

Some options vest in three equal installments on each of the first three anniversaries of the grant date. Other grants vest upon achieving specified company performance criteria evaluated by MDxHealth’s Board of Directors at the end of defined performance periods.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/13/2026 - 04:05 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sollee Joseph

(Last)

(First)

(Middle)

CAP BUSINESS CENTER

ZONE INDUSTRIELLE DES HAUTS-SARTS

(Street)

HERSTAL

BELGIUM

4040

(City)

(State)

(Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option	⁽¹⁾	07/24/2029	Ordinary Shares	23,000	⁽¹⁾	D
Share Option	⁽²⁾	07/15/2030	Ordinary Shares	7,350	⁽²⁾	D
Share Option	⁽³⁾	07/03/2031	Ordinary Shares	17,500	⁽³⁾	D
Share Option	⁽⁴⁾	07/03/2031	Ordinary Shares	17,500	⁽⁴⁾	D
Share Option	⁽⁵⁾	08/03/2032	Ordinary Shares	20,000	⁽⁵⁾	D
Share Option	⁽⁶⁾	08/03/2032	Ordinary Shares	20,000	⁽⁶⁾	D
Share Option	⁽⁷⁾	06/30/2033	Ordinary Shares	20,000	⁽⁷⁾	D
Share Option	⁽⁸⁾	06/30/2033	Ordinary Shares	20,000	⁽⁸⁾	D
Share Option	⁽⁹⁾	06/22/2034	Ordinary Shares	100,000	$2.62	D
Share Option	⁽¹⁰⁾	06/22/2034	Ordinary Shares	65,000	$2.62	D
Share Option	⁽¹¹⁾	04/11/2035	Ordinary Shares	200,000	$1.47	D

Explanation of Responses:

1. Represents options to purchase ordinary shares at a price per share of 12.40 Euros granted on May 14, 2019 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 24, 2019. The options vest in three equal installments on each of the first three anniversaries of the date of grant.

2. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

3. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vest in three equal installments on each of the first three anniversaries of the date of grant.

4. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

5. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vest in three equal installments on each of the first three anniversaries of the date of grant.

6. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

7. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vest in three equal installments on each of the first three anniversaries of the date of grant.

8. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

9. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vest in three equal installments on each of the first three anniversaries of the date of grant.

10. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the performance periods.

11. Represents options to purchase ordinary shares at a price per share of $1.47 granted on March 26, 2025 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on April 11, 2025. The options vest in three equal installments on each of the first three anniversaries of the date of grant.

Remarks:

Executive Vice President of Corporate Development and General Counsel

	/s/ Mark Busch, as attorney-in-fact for Joseph Sollee	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR